ACRV

In October 2025, Acrivon Therapeutics reported its Third Quarter 2025 Financial Results and Business Highlights, including the advancement of ACR-368 and preparation for initial clinical data disclosure for ACR-2316. In December 2025 - January 2026, Acrivon announced a clinical update on its ongoing Phase 2b studies and planned confirmatory Phase 3 trial for ACR-368, initial clinical data on ACR-2316, and other AP3 pipeline updates. In February 2026, Acrivon Therapeutics strengthened its precision medicine therapeutics capabilities with the launch of an internal CLIA-certified laboratory and presented at the TD Cowen 46th Annual Health Care Conference. In March 2026, Acrivon Therapeutics reported Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights and presented preclinical AP3 data at the 2026 AACR Annual Meeting. In April 2026, Acrivon highlighted preclinical data with three posters at AACR and announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). In May 2026, Acrivon Therapeutics is estimated to release its Q1 2026 earnings around May 13th, 2026.